Latest update: 05 desember 2011 .
![]() |
Latest newsletter
(no. 79
December 2011) (previous numbers) |
|
|
NMKL Protocol No 5, 2011 (English) Analytical Quality Control - Guidelines for the publication of analytical results of chemical analyses in foodstuffs Check-list for analytical quality control (AQC) criteria (Word-file)
|
|
|
|
AOAC Europe
- NMKL Symposium 2012
|
|
|
NMKL method number 141 3. Ed "BROCHOTHRIX
spp. määrittäminen lihasta ja lihavalmisteista" is now available also in Finnish.
|
||
|
NMKL newsletter no 78 June 2011
|
||
|
|
||
| No. 78 | ||
| No. 77 | ||
| No. 76 | ||
| No. 75 | ||
| No. 74 | ||
| No. 73 | ||
| No. 72 | ||
| No. 71 | ||
| No. 70 | ||
| No. 69 | ||
| No. 68 | ||
| No. 67 | ||
| No. 66 | ||
| No. 65 | ||
| No. 64 | ||
| No. 63 | ||
| No. 62 | ||
| No. 61 | ||
| No. 60 | ||
| No. 59 | ||
| No. 58 | ||
| No. 57 | ||
| No. 56 | ||
| No. 55/04 | ||
| No. 54/03 | ||
| No. 53/03 | ||
| No. 52/03 | ||
| No. 51/02 | ||
| No. 50/02 | ||
| No. 49/02 | ||
| No. 48/01 | ||
| No. 47/01 | ||
| No. 46/01 | ||
| No. 45/00 | ||
| No. 44/00 | ||
| No. 43/00 | ||
| No. 42/99 | ||
| No. 41/99 | ||
| Back to the top of the page |
This year alarming
news circulated in the public domain that world-wide the production of
cycloheximide is stopped. A non-availability of cycloheximide would have
affected Listeria Enrichment broth (LEB), Buffered
LEB , Oxford agar and Legionella media.
Standardisation bodies (ISO, NORVAL, AFNOR, FDA, USDA-FSIS) have been alerted
and requested to change standards, such as, ISO 11290
part 1 and 2 , IDF 143, FDA
BAM.
Fortunately, Cycloheximide is again produced and can again be purchased, for example, at Calbiochem.
There is no need to re-formulate supplements due to non availability of cycloheximide.
There is no need to change protocols, standards and start an expensive validation procedure.
There is no need, as is done by culture media manufacturers, to replace cycloheximide by amphotericin B (toxicity class Xn+) or natamycin (also known as pimafucin, or pimaricin). The different formulations that recently became available do not contribute to the standardisation of methods.
In the next weeks all cycloheximide containing culture media and supplements will again be available from Merck.
Kind Regards
Dr Peter van Netten